ClinicalTrials.gg
RecruitingNCT06008288Updated Mar 13, 2026

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

A Phase 2 interventional study of JAB-21822 in KRAS P.G12C, Pancreatic Cancer and Solid Tumor, sponsored by Allist Pharmaceuticals, Inc.. Recruiting at 31 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Allist Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 630 studies in Pancreatic Neoplasms with a site in China — 334 open to participants now, 360 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Planned enrollment
189th of 508
88 · median 58
Started
2023
with 63 others
Phase 2
155 of 630
89 open now
Primary completion
2026-12
later than 180 of 359 live
Registered
329th of 630
by date

Among the 630 studies in Pancreatic Neoplasms with a site in China, this one is the 189th largest by planned enrollment of the 508 interventional ones that give a count, is one of 64 that started in 2023, is one of 155 in phase 2, reaches primary completion later than 180 of the 359 other live ones, and was the 329th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

334 of the 630 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

329 more — sign in →

All 334 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and safety of Glecirasib in these patients.

Read the detailed description

This study is a single-arm, multicenter, open-label, basket-design, pivotal phase II trial targeting adult patients with locally advanced or metastatic solid tumors harboring the KRAS p.G12C mutation. The included populations are:

  • Patients with advanced pancreatic cancer who have progressed or are intolerant to prior gemcitabine-based chemotherapy regimens or FOLFIRINOX/mFOLFIRINOX/NALIRIFOX treatments.
  • Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapies or are intolerant and lack satisfactory alternative treatment options.

The study aims to evaluate the efficacy and safety of Glecirasib in these patient populations.

03

Conditions studied

  • KRAS P.G12C
  • Pancreatic Cancer
  • Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with the KRAS p.G12C mutation confirmed through testing using prospectively validated companion diagnostic reagents or clinical trial assay (CTA) methods.
  • or cytologically confirmed locally advanced unresectable or solid tumors (excluding NSCLC and CRC).
  • Patients with pancreatic cancer must have progressed or been intolerant to prior gemcitabine-based chemotherapy regimens or FOLFIRINOX/mFOLFIRINOX/NALIRIFOX treatment. Patients with other types of solid tumors must have progressed or been intolerant to prior systemic therapies and lack satisfactory alternative treatment options.

Exclusion criteria

Exclusion Criteria:

  • Previously received a KRAS G12C inhibitor.
  • History of interstitial lung disease, non-infectious pneumonia, or uncontrolled lung disease (including pulmonary fibrosis, acute lung disease, etc.) with clinical symptoms.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites.
  • Mean corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 .
  • Use of a drug with known risk of torsades de points (TdP) within 14 days prior to the first dose.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    JAB-21822

    Monotherapy

    Drug: JAB-21822

Interventions

  • 800mg, orally QD with 21 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons

    Also known as: Glecirasib

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) by independent central radiological review (IRC) according to RECIST 1.1.

    ORR is defined as the proportion of participants with confirmed complete response or partial response by IRC according to RECIST 1.1.

    Time frame: Approximately 1.5 years

Secondary outcomes

  1. Duration of response (DOR)

    DOR is defined as the time from date of the first objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.

    Time frame: Approximately 1.5 years

  2. Time to response (TTR) by IRC according to RECIST 1.1

    TTR is defined as the duration of time between the date of the first dose and the date of first documented response of either CR or PR.

    Time frame: Approximately 1.5 years

  3. Progression-free survival (PFS) by IRC according to RECIST 1.1

    PFS is defined as time from the first dose until disease progression or death from any cause, whichever occurs first.

    Time frame: Approximately 1.5 years

  4. Disease control rate (DCR) by IRC according to RECIST 1.1

    DCR is defined as the proportion of participants with BOR of CR or PR or stable disease (SD)

    Time frame: Approximately 1.5 years

  5. CA19-9 response rate (Applicable only to pancreatic cancer)

    CA19-9 response rate is defined as the proportion of participants with CA19-9 response (achieving ≥50% decrease in CA19-9 serum levels).

    Time frame: Approximately 1.5 years

  6. Overall survival (OS)

    OS is defined as time from date of the first dose to date of death due to any cause.

    Time frame: Approximately 2.0 years

  7. Number of participants with adverse events

    Participants will be assessed for incidence and severity of AEs according to NCI-CTCAE 5.0 criteria

    Time frame: Approximately 1.5 years

07

Study locations

29 of 31 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 38 months is close to that.

Counting every sponsor, half of 393 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2023
First posted
Aug 23, 2023
StartActual
Oct 27, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06008288
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Oct 27, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 13, 2026

Study contacts

Shanghai Allist Pharmaceuticals Co., Ltd
Contact
zhenhua.gong@allist.com.cn
86-21-80423288
Shanghai Allist Pharmaceuticals
study director · Shanghai Allist Pharmaceuticals Co.,Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glecirasib

Start the discussion